# US 2019/0167634 A1 · Method of treating cancer with combinations of histone deacetylase inhibitors (hdac1) substances

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167634 A1
- Document ID: US20190167634A1
- Status: Published application
- Kind: A1
- Application number: 16/027,146
- Filed: 2018-07-03
- Published: 2019-06-06
- Earliest claimed: 2011-07-14
- Assignees: Research Cancer Institute of America
- Applicants: Research Cancer Institute of America
- Inventors: Mohammed Amin Nezami
- Web page: https://patentgrep.com/patent/US20190167634A1

## CPC

- A61K 31/385: having two or more sulfur atoms in the same ring
- A61G 10/026: {for hyperbaric oxygen therapy}
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61H 2033/143: {with oxygen}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61G: TRANSPORT, PERSONAL CONVEYANCES OR ACCOMMODATION SPECIALLY ADAPTED FOR PATIENTS OR DISABLED PERSONS (appliances for aiding patients or disabled persons to walk A61H3/00); OPERATING TABLES OR CHAIRS; CHAIRS FOR DENTISTRY; FUNERAL DEVICES (embalming corpses A01N1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61H: PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY (electrotherapy, magnetotherapy, radiation therapy or ultrasound therapy A61N)

## Abstract

A method for treating cancer is described using combination therapies comprising the use of hyperbaric oxygen with histone deacetylase inhibitors, with and without glycolytic therapies. The patient is subjected to a hyperbaric environment of substantially pure oxygen. A predetermined dose of one or more HDACI substances is administered to the patient. In addition, glycolitic inhibitors may also be administered. Dosages, pressures, and durations are selected as described herein to have a therapeutic effect on the patient.

## Claims

### Claim 1

A method for treating a patient having cancer, comprising:
administering a predetermined dose of one or more HDACI substances to the patient; and,
subjecting the patient to a hyperbaric pressure environment of substantially pure oxygen;
said predetermined dose, hyperbaric pressure, and the duration of said subjection being selected to have a therapeutic affect on said cancer.

### Claim 2 (depends on 1)

The method of claim 1 wherein said duration is substantially one hour.

### Claim 3 (depends on 1)

The method of claim 1 wherein said hyperbaric pressure is substantially between one and one half to two atmospheres.

### Claim 4 (depends on 1)

The method of claim 1 wherein the subjecting step is carried out within about one hour from the administering step.

### Claim 5 (depends on 1)

The method of claim 1 wherein the HDACI substance is selected from the group consisting of sodium phenyl butyrate, quercetin, lipoic acid; and combinations thereof.

### Claim 6 (depends on 1)

The method of claim 1 wherein a therapeutic amount of one or more additional substances is administered selected from the group consisting of DCA, 3BP, and octreotide.

### Claim 7 (depends on 1)

The method of claim 1 wherein said dose is administered either orally or intravenously or both.

### Claim 8

A composition for treating cancer comprising a predetermined dose of one or more HDACI substances.